Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Shi

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
JAMA|November 16, 2021
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical TrialBurkert Pieske, Rolf Wachter, Sanjiv J Shah, et al.
European Journal of Heart Failure|November 23, 2017
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION studyMichele Senni, John J V McMurray, Rolf Wachter, et al.
ESC Heart Failure|April 17, 2020
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trialRolf Wachter, Sanjiv J Shah, Martin R Cowie, et al.
European Journal of Heart Failure|June 25, 2021
Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fractionSanjiv J Shah, Martin R Cowie, Rolf Wachter, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
The New England Journal of Medicine|December 5, 2008
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsKenneth Jamerson, Michael A Weber, George L Bakris, et al.
JACC. Heart Failure|July 11, 2016
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF TrialScott D Solomon, Brian Claggett, Milton Packer, et al.
The New England Journal of Medicine|December 3, 2015
Estimating the Long-Term Treatment Benefits of Sacubitril-ValsartanBrian Claggett, Milton Packer, John J V McMurray, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 7, 2011
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertensionThomas Wells, Jeffrey Blumer, Kevin E C Meyers, et al.
European Heart Journal|March 30, 2020
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fractionMuthiah Vaduganathan, Pardeep S Jhund, Brian L Claggett, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
JAMA|November 16, 2021
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical TrialBurkert Pieske, Rolf Wachter, Sanjiv J Shah, et al.
European Journal of Heart Failure|November 23, 2017
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION studyMichele Senni, John J V McMurray, Rolf Wachter, et al.
ESC Heart Failure|April 17, 2020
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trialRolf Wachter, Sanjiv J Shah, Martin R Cowie, et al.
European Journal of Heart Failure|June 25, 2021
Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fractionSanjiv J Shah, Martin R Cowie, Rolf Wachter, et al.
Circulation. Heart Failure|June 15, 2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF TrialAkshay S Desai, Scott Solomon, Brian Claggett, et al.
The New England Journal of Medicine|December 5, 2008
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsKenneth Jamerson, Michael A Weber, George L Bakris, et al.
JACC. Heart Failure|July 11, 2016
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF TrialScott D Solomon, Brian Claggett, Milton Packer, et al.
The New England Journal of Medicine|December 3, 2015
Estimating the Long-Term Treatment Benefits of Sacubitril-ValsartanBrian Claggett, Milton Packer, John J V McMurray, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 7, 2011
Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertensionThomas Wells, Jeffrey Blumer, Kevin E C Meyers, et al.
European Heart Journal|March 30, 2020
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fractionMuthiah Vaduganathan, Pardeep S Jhund, Brian L Claggett, et al.
Pageof 7